Precigen to host a webcast on june 3rd to detail pivotal study results of prgn-2012 in recurrent respiratory papillomatosis presented at the 2024 asco annual meeting

Germantown, md. , may 23, 2024 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the company will host a webcast on june 3, 2024 at 6:00 pm ct/7:00 pm et following the late-breaking oral presentation of results from the pivotal study of prgn-2012 for the treatment of recurrent respiratory papillomatosis (rrp) at the 2024 american society of clinical oncology (asco) annual meeting.
PGEN Ratings Summary
PGEN Quant Ranking